IOVA Iovance Biotherapeutics (IOVA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001425205
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
174
13F, latest reported quarter
Conversions, 180 days
17
Codes C/M, not in net · $0 priced
Iovance Biotherapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for IOVANCE BIOTHERAPEUTICS, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 30,000 shares held after it.
- 2 other insiders bought within 30 days.
- 174 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Kirby Daniel Gordon bought about $55.2K of IOVA on Jun 5, 2025, the largest insider purchase at the company since 2024; 2 other insiders bought within 30 days and 174 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 2.7% of the 206,852 shares held after it.
- 2 other insiders bought within 30 days.
- 174 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Regulatory Officer Puri Raj K. bought about $9.7K of IOVA on May 23, 2025; 2 other insiders bought within 30 days and 174 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Nov 28, 2022.
- +42.1% median (+42.1% mean) 90-day return after 2 previous buys.
- The trade is 6.7% of the 374,646 shares held after it.
- 2 other insiders bought within 30 days.
- 174 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Interim CEO & General Counsel Vogt Frederick G bought about $42.2K of IOVA on May 14, 2025, the largest insider purchase at the company since 2024; 2 other insiders bought within 30 days and 174 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 31, 2022.
- The trade is 666.7% of the 7,500 shares held after it.
- No other insider sold within 30 days.
- 174 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Maynard Ryan D sold about $503.0K of IOVA on Nov 12, 2024, the largest insider sale at the company on our record; 174 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Sep 18, 2023.
- +20.5% median (+26.4% mean) 90-day return after 5 previous buys.
- The trade is 78.1% of the 320,150 shares held after it.
- 2 other insiders bought within 30 days.
- 174 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MCPEAK MERRILL A bought about $2.3M of IOVA on Feb 20, 2024; 2 other insiders bought within 30 days and 174 funds added in the latest 13F quarter.23 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
174 funds bought in last quarter
more than 86% of Pharma & Biotech
Revenue
+60.6% year over year
more than 80% of Pharma & Biotech
Margin
-148.4% net margin
below 62% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
16.4% of the float short (float per yahoo 2026-10-26) · 2.8 days to cover · settled 2026-09-30
more than 83% of Pharma & Biotech
The situation: each line is one rule over one dataset
1 clinical trial was terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch IOVA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+555.3%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns IOVA: institutional holders (13F)
13F holdings, latest reported quarter
36,957,681 sh
$153.7M
28,967,103 sh
$120.5M
24,478,268 sh
$101.8M
19,010,697 sh
$79.1M
18,204,248 sh
$75.7M
Congress trades in IOVA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
IOVA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
IOVA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Genomics Immunology and Healthcare ETF
$3.4M position · as of 2026-07-31
1.8%
Virtus Biotech Etf
$1.4M position · as of 2026-07-31
1.4%
Tema Oncology ETF
$1.1M position · as of 2026-05-31
0.7%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$60.3M position · as of 2026-06-30
0.6%
PROFUND VP BIOTECHNOLOGY
$267.3K position · as of 2026-06-30
0.5%
BIOTECHNOLOGY ULTRASECTOR PROFUND
$562.4K position · as of 2026-07-31
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
15 registered trials, 8 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 1
0 active
8
Phase 2
4 active
1
Phase 3
1 active
1
Not applicable
0 active
3
Multi-phase
3 active
What changed recently
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young A
2026-10-17 · Active Not Recruiting → Terminated · After reviewing the available safety and efficacy data to date, Iovance has made the decision to conclude all remaining participant visits.
Phase 1
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tiss
2026-10-10 · Not Yet Recruiting → Recruiting
Phase 2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Frederick GVogt
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$11.0M
$7.0M
$3.3M
-73%
+18%
2023
$4.8M
$5.2M
$1.7M
-71%
+19%
2022
$5.3M
-$173.2K
$2.2M
-77%
+14%
2020
$9.0M
$22.0M
$2.6M
+68%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 174 funds added last quarter. Each figure is a federal filing, dated the day it went public.
IOVA financials
Revenue growth
+60.6%
XBRL, annual
Net margin
-148.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$325.0M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM IOVA
| FY Dec 2025 | $263.5M |
| FY Dec 2024 | $164.1M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | $0 |
| FY Dec 2021 | $0 |
| Jun 2026 | $99.3M |
| Mar 2026 | $71.4M |
| Dec 2025 | $86.8M |
| Sep 2025 | $67.5M |
| Jun 2025 | $60.0M |
| Mar 2025 | $49.3M |
| Dec 2024 | $73.7M |
| Sep 2024 | $58.6M |
At each fiscal year end
Single quarter
Net margin, TTM
-89.1%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM IOVA
| FY Dec 2025 | -148.4% |
| FY Dec 2024 | -226.9% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -47.6% |
| Mar 2026 | -110.7% |
| Dec 2025 | -82.9% |
| Sep 2025 | -135.3% |
| Jun 2025 | -186.2% |
| Mar 2025 | -235.5% |
| Dec 2024 | -106.6% |
| Sep 2024 | -142.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$296.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM IOVA
| FY Dec 2025 | -$336.2M |
| FY Dec 2024 | -$364.0M |
| FY Dec 2023 | -$384.1M |
| FY Dec 2022 | -$313.2M |
| FY Dec 2021 | -$265.5M |
| Jun 2026 | -$66.3M |
| Mar 2026 | -$78.7M |
| Dec 2025 | -$61.9M |
| Sep 2025 | -$89.5M |
| Jun 2025 | -$74.9M |
| Mar 2025 | -$109.9M |
| Dec 2024 | -$77.5M |
| Sep 2024 | -$61.3M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity IOVA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt IOVA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-40.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity IOVA
| FY Dec 2025 | -55.5% |
| FY Dec 2024 | -57.5% |
| FY Dec 2023 | -81.9% |
| FY Dec 2022 | -70.6% |
| FY Dec 2021 | -53.6% |
| Jun 2026 | -40.4% |
| Mar 2026 | -47.5% |
| Dec 2025 | -55.5% |
| Sep 2025 | -53.9% |
| Jun 2025 | -53.2% |
| Mar 2025 | -51.9% |
| Dec 2024 | -57.5% |
| Sep 2024 | -56.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-31.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets IOVA
| FY Dec 2025 | -42.9% |
| FY Dec 2024 | -44.0% |
| FY Dec 2023 | -61.5% |
| FY Dec 2022 | -54.9% |
| FY Dec 2021 | -44.3% |
| Jun 2026 | -31.8% |
| Mar 2026 | -37.4% |
| Dec 2025 | -42.9% |
| Sep 2025 | -41.9% |
| Jun 2025 | -41.7% |
| Mar 2025 | -40.9% |
| Dec 2024 | -44.0% |
| Sep 2024 | -44.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital IOVA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-38.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed IOVA
| FY Dec 2025 | -51.6% |
| FY Dec 2024 | -54.2% |
| FY Dec 2023 | -74.1% |
| FY Dec 2022 | -63.3% |
| FY Dec 2021 | -48.9% |
| Jun 2026 | -38.0% |
| Mar 2026 | -44.3% |
| Dec 2025 | -51.6% |
| Sep 2025 | -50.4% |
| Jun 2025 | -49.8% |
| Mar 2025 | -48.9% |
| Dec 2024 | -54.2% |
| Sep 2024 | -52.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing IOVA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value IOVA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-4.6%
TTM free cash flow over market value at close 2026-10-23
FCF yield IOVA
| FY Dec 2025 | -31.0% |
| FY Dec 2024 | -16.1% |
| FY Dec 2023 | -18.5% |
| FY Dec 2022 | -31.1% |
| FY Dec 2021 | -8.9% |
| Jun 2026 | -16.0% |
| Mar 2026 | -21.1% |
| Dec 2025 | -31.0% |
| Sep 2025 | -44.8% |
| Jun 2025 | -56.3% |
| Mar 2025 | -31.8% |
| Dec 2024 | -16.1% |
| Sep 2024 | -13.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing IOVA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $263.5M | $164.1M | $1.2M | n/a |
| Operating income | -$403.4M | -$395.3M | -$460.6M | -$398.9M |
| Net income | -$391.0M | -$372.2M | -$444.0M | -$395.9M |
| EPS (diluted) | -1.09 | -1.28 | -1.89 | -2.49 |
| Operating cash flow | -$302.4M | -$353.0M | -$361.8M | -$292.8M |
| Cash | $163.1M | $115.7M | $114.9M | $231.7M |
SEC XBRL, fiscal years, as known on 2026-10-27
IOVA Stock Sonar score 4/7 axes
Find similar shapesCompareIOVA ranks highest on institutional and government (86th percentile) and growth (80th), and lowest on risk and compliance (37th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
